新型阴茎牵引装置治疗佩罗尼氏病男性的结局:一项随机、单盲、对照试验
该随机、单盲、意向性治疗试验将110例佩罗尼氏病患者按3:1分配至每日30至90分钟阴茎牵引治疗组或无治疗对照组,为期3个月。结果显示牵引组在阴茎长度、弯曲度和勃起功能方面均较对照组有显著改善,且耐受性良好,仅见短暂轻微不良事件。
要点
- 每日30至90分钟阴茎牵引治疗3个月可安全改善佩罗尼氏病患者的阴茎弯曲度和长度。
- 牵引组阴茎长度增加1.5 cm vs 对照组0 cm(p<0.001),弯曲度改善-11.7度 vs 1.3度(p<0.01)。
- 合并勃起功能障碍者牵引组国际勃起功能指数-勃起功能评分改善4.3 vs 对照组-0.7(p=0.01)。
核心结论
- 每日30至90分钟RestoreX装置阴茎牵引治疗安全,可显著且临床有意义地改善佩罗尼氏病患者的阴茎弯曲度和长度,并改善合并勃起功能障碍者的勃起功能,无显著不良事件。
研究设计与样本
- 随机、对照、单盲、意向性治疗试验(ClinicalTrials.gov NCT03389854),纳入弯曲度30度或以上的佩罗尼氏病患者,按3:1随机分配至阴茎牵引治疗装置每日30至90分钟组或无治疗对照组,为期3个月,共110例男性。
主要发现
- 牵引组阴茎长度改善1.5 cm vs 对照组0 cm(p<0.001),弯曲度改善-11.7度 vs 对照组1.3度(p<0.01)。
- 合并勃起功能障碍者中,牵引组国际勃起功能指数-勃起功能评分改善4.3 vs 对照组-0.7(p=0.01)。
- 牵引组77%的患者弯曲度改善(应答者中28.2%平均改善-17.2度),94%的患者长度增加(10.9%增加1.6 cm)。
- 反向弯曲和白线指示器提高了疗效;曾使用其他阴茎牵引装置的患者100%偏好RestoreX装置。
临床怎么用
- 作者认为每日30至90分钟RestoreX装置阴茎牵引治疗是安全且有效的选择,可改善佩罗尼氏病患者的阴茎弯曲度和长度,并改善合并勃起功能障碍者的勃起功能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Current penile traction therapy devices have significant limitations, including the need to use them for 3 to 8 hours per day. Given these issues, the novel RestoreX® penile traction therapy device was developed in cooperation with Mayo Clinic. MATERIALS AND METHODS: We performed a randomized, controlled, single-blind, intent to treat trial (ClinicalTrials.gov NCT03389854) in men with Peyronie's disease who were assigned to the penile traction therapy device for 30 to 90 minutes per day or to no therapy for 3 months. Study inclusion criteria were curvature 30 degrees or greater with no study exclusions due to complex curvature, hourglass deformity, prior Peyronie's disease therapy or surgery, or calcification. The primary outcome was safety and secondary outcomes were penile length and curvature, and questionnaire responses. RESULTS: A total of 110 men were randomized 3:1 to the penile traction therapy group or the control group. The cohorts were well matched with a mean age of 58.4 years, a 49.7-month Peyronie's disease history and 59.3 degree curvature. Overall penile traction therapy was well tolerated with only transient and mild adverse events reported. At 3 months men undergoing penile traction therapy demonstrated significant improvements over controls in penile length (1.5 vs 0 cm, p <0.001), curvature (-11.7 vs 1.3 degrees, p <0.01) and erectile function (4.3 vs -0.7, p = 0.01) according to the International Index of Erectile Function-Erectile Function among men with erectile dysfunction. Overall 77% of the men on penile traction therapy experienced improved curvature (mean -17.2 degrees in 28.2% of responders) while 94% achieved increased length (1.6 cm in 10.9%). Counter bending and the white line indicator improved efficacy, validating key device innovations. Of men who had previously used other penile traction therapy devices 100% preferred the RestoreX device. CONCLUSIONS: Penile traction therapy with the RestoreX device for 30 to 90 minutes per day was safe, and resulted in significant and clinically meaningful improvements in penile curvature and length in men with Peyronie's disease, and in erectile function in men with erectile dysfunction and Peyronie's disease with no significant adverse events. To our knowledge these data represent the only reported improvements for any device used less than 3 to 8 hours per day.
引用
- Ziegelmann M, Savage J, Toussi A, et al. Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial. J Urol. 2019. PMID: 30916626. doi:10.1097/JU.0000000000000245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。